<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01288807</url>
  </required_header>
  <id_info>
    <org_study_id>100686</org_study_id>
    <nct_id>NCT01288807</nct_id>
  </id_info>
  <brief_title>Effect of Milnacipran on Pain in Fibromyalgia</brief_title>
  <acronym>Forest</acronym>
  <official_title>Effects of a 12 Week Milnacipran 200 mg Treatment on Pain Perception and Pain Processing in Fibromyalgia - An Open Label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to study the effects of milnacipran treatment on neurotransmitter
      release in fibromyalgia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fibromyalgia (FM) is a chronic pain condition with significant morbidity. Current research
      suggests a primarily central mediation of the widespread pain including central sensitization
      at the spinal level and abnormal pain processing at the cerebral level. Findings in FM
      patients include abnormal neurotransmitter levels in cerebrospinal fluid (CSF), abnormal
      activation of cerebral pain processing areas and abnormal peripheral pain and sensory
      thresholds. Continuous low level spinal cord activation by primary nociceptive afferents (C
      and A delta fibers) is believed to significantly drive the central sensitization. One major
      spinal neurotransmitter released by these pain fibers is substance P (SP). Several studies
      have shown that FM patients have up to three times higher baseline SP levels in the CSF
      compared to controls. Since spinal neurotransmitter release and therefore nociceptive
      afferent activity is also regulated via a descending inhibitory pathway releasing
      norepinephrine (NE) and serotonin (5HT), decreased activity of this pain modulating system
      could also be involved in abnormal pain processing in FM. Indeed, there is support in the
      literature for decreased CSF levels of both NE and 5HT or their metabolites. Milnacipran, a
      NE and 5HT reuptake inhibitor, has been shown to potentially effectively reduce FM pain and
      symptoms of FM by affecting the above pathologies.

      The investigators propose an open label clinical trial with milnacipran 200 mg over 12-weeks
      in order to investigate the pain pathway in FM patients at peripheral and spinal levels
      before and after treatment. In addition, the investigators will assess pain intensity and
      symptoms of FM before, during and after treatment. To determine if there are peripheral
      effects, the investigators will characterize the systemic neurotransmitter release and their
      metabolites in plasma. The investigators will also measure the heart rate variability using
      an electrocardiogram to look for effects on the sympathetic nervous system.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Substance P in Cerebrospinal Fluid in Response to Experiemental Pain Before and After Milnacipran Treatment.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measure levels of Substance P present in serial samples of CSF and plasma collected over the course of 4 hours in response to application of a painful thermal stimulus at baseline (&quot;before&quot;) and the end of 12 weeks of treatment with milnacipran 200mg daily (&quot;after&quot;).
Substance P levels are presented. Presented data show the 10 minute and 40 minute timepoint for Substance P after pain challenge. Additional time points were not analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure Sensory Threshold for Temperature Pain</measure>
    <time_frame>12 weeks</time_frame>
    <description>Investigators will utilize quantitative sensory testing to assess changes in sensory thresholds among patients with fibromyalgia before and after a twelve (12) week course of milnacipran.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure Sensory Thresholds for Pressure Pain</measure>
    <time_frame>12 weeks</time_frame>
    <description>Investigator will utilize sensory testing to assess changes in sensory thresholds among patients with fibromyalgia before and after a twelve (12) week course of milnacipran.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure Pain Ratings and Fibromyalgia Symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>Fibromyalgia patients will be asked to keep a pain diary which assess spontaneous pain ratings daily, a subjective weekly assessment, as well as degree of improvement weekly during treatment period on a numeric rating scale.
The Numeric Pain Rating Scale (NPRS) is assessing the patients pain on a 11-point rating scale from 0 - 10 with 0 corresponding to 'No Pain' and 10 corresponding to 'Worst Pain imaginable'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure Concentrations of Serotonin and Norepinephrine Cerebrospinal Fluid and Plasma</measure>
    <time_frame>12 weeks</time_frame>
    <description>The investigators will measure cerebrospinal fluid and plasma concentrations of serotonin and norepinephrine in CSF and plasma before and after twelve (12) weeks of treatment with milnacipran.
Assays for these outcomes were not performed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Titrated Milnacipram doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milnacipram</intervention_name>
    <description>Titration to 200mg PO daily</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Savella</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female age 18 or older

          -  Written informed consent and written release of health and research study information

          -  Diagnosis of Fibromyalgia

          -  Participant has pain greater than 4 on the NRS of 0 to 10 on average over the last
             week prior to initial evaluation that interferes with function most days per week

          -  Pain duration greater than 6 months

          -  Negative urine pregnancy test on experimental day 1 and 2 and on first day of
             treatment prior to administration of study medication and fluoroscopy

          -  Ability to speak and understand English, to follow instructions, and fill out study
             questionnaires

          -  Likely to complete all required visits

          -  Must be ambulatory and able to lay prone for 30 minutes

        Exclusion Criteria:

          -  Any condition or situation that in the investigator's opinion may put the participant
             at significant risk, confound the study results, or interfere significantly with the
             participant's participation in the study

          -  Serious, unstable medical illness that could lead to hospitalization over the next
             three months; and/or a DSM-IV diagnosis(es) with active problems within the last six
             months, such as: schizophrenia, bipolar disorder, antisocial personality disorder, or
             substance use disorder

          -  Known, uncontrolled, serious systemic disease, including: hypertension and/or
             tachyarrythmia

          -  Females who are pregnant, breast feeding, or who plan to become pregnant, or who may
             potentially become pregnant

          -  Allergy or sensitivity to any component of the study medication or to contrast dye

          -  Patients on coumadin, heparin, or any other known increase risk of bleeding

          -  Signs of increased intracranial pressure

          -  Patients who are unable to continue current pain medication

          -  Allergy or contraindication to acetaminophen

          -  Use of monoamine oxidase inhibitors

          -  Uncontrolled narrow-angle glaucoma
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Moeller-Bertram, MD, PhD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Medical Center, La Jolla</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 1, 2011</study_first_submitted>
  <study_first_submitted_qc>February 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2011</study_first_posted>
  <results_first_submitted>August 7, 2019</results_first_submitted>
  <results_first_submitted_qc>September 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 24, 2019</results_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Tobias Moeller-Bertram</investigator_full_name>
    <investigator_title>MD, PhD, MAS Associate Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Fibromyalgia</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Milnacipran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Titrated Milnacipram doses
Milnacipram: Titration to 200mg PO daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Titrated Milnacipram doses
Milnacipram: Titration to 200mg PO daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.4" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Concentration of Substance P in Cerebrospinal Fluid in Response to Experiemental Pain Before and After Milnacipran Treatment.</title>
        <description>Measure levels of Substance P present in serial samples of CSF and plasma collected over the course of 4 hours in response to application of a painful thermal stimulus at baseline (&quot;before&quot;) and the end of 12 weeks of treatment with milnacipran 200mg daily (&quot;after&quot;).
Substance P levels are presented. Presented data show the 10 minute and 40 minute timepoint for Substance P after pain challenge. Additional time points were not analyzed.</description>
        <time_frame>12 weeks</time_frame>
        <population>8 patients with fibromyalgia were recruited for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Titrated Milnacipram doses
Milnacipram: Titration to 200mg PO daily</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Substance P in Cerebrospinal Fluid in Response to Experiemental Pain Before and After Milnacipran Treatment.</title>
          <description>Measure levels of Substance P present in serial samples of CSF and plasma collected over the course of 4 hours in response to application of a painful thermal stimulus at baseline (&quot;before&quot;) and the end of 12 weeks of treatment with milnacipran 200mg daily (&quot;after&quot;).
Substance P levels are presented. Presented data show the 10 minute and 40 minute timepoint for Substance P after pain challenge. Additional time points were not analyzed.</description>
          <population>8 patients with fibromyalgia were recruited for the study.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.2" spread="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 min after pain challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.7" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 min after pain challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>repeated measure ANOVA</non_inferiority_desc>
            <p_value>&lt; 0.01</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure Sensory Threshold for Temperature Pain</title>
        <description>Investigators will utilize quantitative sensory testing to assess changes in sensory thresholds among patients with fibromyalgia before and after a twelve (12) week course of milnacipran.</description>
        <time_frame>12 weeks</time_frame>
        <population>8 patients with fibromyalgia syndrom were recruited.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Titrated Milnacipram doses
Milnacipram: Titration to 200mg PO daily</description>
          </group>
        </group_list>
        <measure>
          <title>Measure Sensory Threshold for Temperature Pain</title>
          <description>Investigators will utilize quantitative sensory testing to assess changes in sensory thresholds among patients with fibromyalgia before and after a twelve (12) week course of milnacipran.</description>
          <population>8 patients with fibromyalgia syndrom were recruited.</population>
          <units>Degree Celcius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cold threshold before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cold threshold after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis looks at the cold threshold measured in degrees celcius before and after treatment.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>two-tailed paired t-test</non_inferiority_desc>
            <p_value>&lt; 0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure Sensory Thresholds for Pressure Pain</title>
        <description>Investigator will utilize sensory testing to assess changes in sensory thresholds among patients with fibromyalgia before and after a twelve (12) week course of milnacipran.</description>
        <time_frame>12 weeks</time_frame>
        <population>8 patients with fibromyalgia syndrom were recruited</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Titrated Milnacipram doses
Milnacipram: Titration to 200mg PO daily</description>
          </group>
        </group_list>
        <measure>
          <title>Measure Sensory Thresholds for Pressure Pain</title>
          <description>Investigator will utilize sensory testing to assess changes in sensory thresholds among patients with fibromyalgia before and after a twelve (12) week course of milnacipran.</description>
          <population>8 patients with fibromyalgia syndrom were recruited</population>
          <units>lb/in(2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pressure threshold before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pressure threshold after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis looks at the pressure threshold measured in pounds per square inch before and after treatment</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt; 0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure Pain Ratings and Fibromyalgia Symptoms</title>
        <description>Fibromyalgia patients will be asked to keep a pain diary which assess spontaneous pain ratings daily, a subjective weekly assessment, as well as degree of improvement weekly during treatment period on a numeric rating scale.
The Numeric Pain Rating Scale (NPRS) is assessing the patients pain on a 11-point rating scale from 0 - 10 with 0 corresponding to 'No Pain' and 10 corresponding to 'Worst Pain imaginable'.</description>
        <time_frame>12 weeks</time_frame>
        <population>8 patients with fibromyalgia syndrom were recruited.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Titrated Milnacipram doses
Milnacipram: Titration to 200mg PO daily</description>
          </group>
        </group_list>
        <measure>
          <title>Measure Pain Ratings and Fibromyalgia Symptoms</title>
          <description>Fibromyalgia patients will be asked to keep a pain diary which assess spontaneous pain ratings daily, a subjective weekly assessment, as well as degree of improvement weekly during treatment period on a numeric rating scale.
The Numeric Pain Rating Scale (NPRS) is assessing the patients pain on a 11-point rating scale from 0 - 10 with 0 corresponding to 'No Pain' and 10 corresponding to 'Worst Pain imaginable'.</description>
          <population>8 patients with fibromyalgia syndrom were recruited.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain rating before treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain rating after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt; 0.05</p_value>
            <p_value_desc>one-way repeated measure ANOVA</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure Concentrations of Serotonin and Norepinephrine Cerebrospinal Fluid and Plasma</title>
        <description>The investigators will measure cerebrospinal fluid and plasma concentrations of serotonin and norepinephrine in CSF and plasma before and after twelve (12) weeks of treatment with milnacipran.
Assays for these outcomes were not performed.</description>
        <time_frame>12 weeks</time_frame>
        <population>Assays for Norepinephrine and Serotonin were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Titrated Milnacipram doses
Milnacipram: Titration to 200mg PO daily</description>
          </group>
        </group_list>
        <measure>
          <title>Measure Concentrations of Serotonin and Norepinephrine Cerebrospinal Fluid and Plasma</title>
          <description>The investigators will measure cerebrospinal fluid and plasma concentrations of serotonin and norepinephrine in CSF and plasma before and after twelve (12) weeks of treatment with milnacipran.
Assays for these outcomes were not performed.</description>
          <population>Assays for Norepinephrine and Serotonin were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over the duration of the study (12 weeks).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Titrated Milnacipram doses
Milnacipram: Titration to 200mg PO daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>One patient required temporarily lowering the study drug dose from 200mg to 100mg for one week due to nausea that resolved spontaneously.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tobias Moeller-Bertram (PI)</name_or_title>
      <organization>UCSD</organization>
      <phone>7603211315</phone>
      <email>moellerbertram@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

